FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugs
FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugs 5/1/2024
FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugs 5/1/2024